CollPlant Biotechnologies (CLGN) Set to Announce Earnings on Wednesday

Posted by Defense World Staff on Nov 20th, 2024

CollPlant Biotechnologies (NASDAQ:CLGN – Get Free Report) will release its earnings data before the market opens on Wednesday, November 27th. Analysts expect CollPlant Biotechnologies to post earnings of ($0.37) per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

CollPlant Biotechnologies (NASDAQ:CLGN – Get Free Report) last released its earnings results on Tuesday, August 20th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). The business had revenue of $0.25 million during the quarter, compared to analysts’ expectations of $0.70 million. CollPlant Biotechnologies had a negative return on equity of 65.98% and a negative net margin of 2,535.70%. On average, analysts expect CollPlant Biotechnologies to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

CollPlant Biotechnologies Stock Up 1.0 %

Shares of NASDAQ:CLGN opened at $4.19 on Wednesday. CollPlant Biotechnologies has a 52-week low of $3.61 and a 52-week high of $6.99. The stock has a market cap of $47.98 million, a P/E ratio of -2.72 and a beta of 0.44. The business has a fifty day moving average of $4.38 and a two-hundred day moving average of $4.92.

Analysts Set New Price Targets

A number of research analysts have commented on CLGN shares. EF Hutton Acquisition Co. I upgraded CollPlant Biotechnologies to a “strong-buy” rating in a research note on Monday, August 5th. HC Wainwright reaffirmed a “buy” rating and set a $11.00 price objective on shares of CollPlant Biotechnologies in a research report on Wednesday, August 21st.

Check Out Our Latest Stock Report on CLGN

CollPlant Biotechnologies Company Profile

(Get Free Report)

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.